Tag: EU HTA
JCA Does Not Replace National HTA: A Technical Readiness Guide for Market Access Teams
JCA Does Not Replace National HTA: A Technical Readiness Guide for Market Access Teams The European Union Health Technology Assessment Regulation has created a common framework for assessing the relative clinical effectiveness and safety of eligible health technologies. However, the introduction of Joint Clinical Assessment does not establish a single European pricing, reimbursement or market-access…
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission How pre-submission evidence reviews are becoming the next competitive advantage for pharmaceutical and biotech companies in Europe. The pharmaceutical industry has entered a new era of evidence generation. For years, achieving regulatory approval was considered the biggest milestone on the path to…
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Pharma’s Competitive Advantage Under EU HTA
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Becoming Pharma’s Competitive Advantage Under EU HTA How cross-functional collaboration, Real-World Evidence, AI, and early planning are reshaping successful market access strategies across Europe. The European pharmaceutical landscape is changing rapidly. Over the past year, discussions around the EU Health Technology Assessment (HTA) Regulation…
